Multidrug resistance-associated protein and mutant p53 protein expression in non-small cell lung cancer

Modern Pathology

Volumn 11, Issue 11, 1998, Pages 1059-1063

  Oshika, Yoshiro ^a   Nakamura, Masato ^a   Tokunaga, Tetsuji ^a   Fukushima, Yoshitaka ^a   Abe, Yoshiyuki ^a   Ozeki, Yuichi ^b   Yamazaki, Hitoshi ^a   Tamaoki, Norikazu ^a   Ueyama, Yoshito ^a,c  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^c CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

Author keywords

Coexpression; Multidrug resistance associated protein; Non small cell lung cancer; p53; Prognosis

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; PROTEIN P53; VINDESINE;

ADULT; AGED; ARTICLE; FEMALE; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031787102     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Williams CJ. Chemotherapy of non-small cell lung cancer. Br J Cancer 1989;60:9-11.
2. Britran JD, Golomb HM, Little AG, Weichselbaum RR Lung cancer: a comprehensive treatise. Orlando, FL: Grune & Stratton; 1988. p. 173-241, 307-97.
3. Richards F II, Perry DJ, Goutsou M, Modeas C, Muchmore E, Rege V, et al. Chemotherapy with 5-fluorouracil (5-FU) and cisplatin or 5-FU, cisplatin, and vinblastine for advanced non-small cell lung cancer. Cancer 1991;67:2974-9.
4. Dhingra HM, Valdivieso M, Carr DT, Chiuten DF, Farha P, Murphy WK, et al. Randomized trial of three combinations of cisplatin with vindesine and/ or VP-16-213 in the treatment of advanced non-small cell lung cancer. J Clin Oncol 1985;3:176-83.
5. Fojo AT, Whang-Peng J, Gottesman MM, Pastan I. Amplification of DNA sequences in human multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci U S A 1985;82: 7661-5.
6. Gros P, Neriah YB, Croop JM, Housman DE. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 1986;323:728-31.
7. Giaccone G, Gazdar AF, Beck H, Zunino F, Capranico G. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res 1992;52:1666-74.
8. Abe Y, Nakamura M, Ota E, Ozeki Y, Tamai S, Inoue H, et al. Expression of the multidrug resistance gene (MDR1) in non-small cell lung cancer. Jpn J Cancer Res 1994;85:536-41.
9. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-4.
10. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994;54:357-61.
11. Ota E, Abe Y, Oshika Y, Ozeki Y, Iwasaki M, Inoue H, et al. Expression of the multidrug resistance-associated protein (MRP) gene in non-small cell lung cancer. Br J Cancer 1995; 72:550-4.
12. Casey G, Lopez ME, Ramos JC, Plummer SJ, Arboleda MJ, Shaughnessy M, et al. DNA sequence analysis of exon 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 1996;13:1971-81.
13. World Health Organization. The world health organization histological typing of lung tumours. Am J Clin Pathol 1982; 77:123-36.
14. Abe Y, Yamazaki H, Oshika Y, Suto R, Tsugu A, Ota E, et al. Advantage of in vivo chemosensitivity assay to detect vincristine resistance in the human tumor xenograft. Anticancer Res 1996;16:729-34.
15. Nooter K, Bosnian FT, Burger H, van Wingerden KE, Flens MJ, Scheper RJ, et al. Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small cell lung cancer. Ann Oncol 1996;7:75-81.
16. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989;58: 137-71.
17. Sugawara I, Yamada H, Nakamura H, Sumizawa T, Akiyama S, Masunaga A, et al. Preferential expression of the multidrug-resistance-associated protein (MRP) in adenocarcinoma of the lung. Int J Cancer 1995;64:322-5.
18. Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 1992;255:459-62.
19. Zaman GJR, Versantvoort CHM, Smit JJM, Eijdems EWHM, De Haas M, Smith AJ, et al. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res 1993;53:1747-50.
20. Stewart AJ, Canitrot Y, Barcchini E, Dean NM, Deely RG, Cole SPC. Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides. Biochem Pharmacol 1996;51: 461-9.
21. Gekeler V, Ise W, Sanders KH, Ulrich WR, Beck J. The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP-associated multidrug resistance. Biochem Biophys Res Commun 1995;208:345-52.
22. Twentyman PR, Versantvoort CHM. Experimental modulation of MRP (multidrug resistance-associated protein)-mediated resistance. Eur J Cancer 1996;32A:1002-9.